Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Peptide Nano-Enzymes
- Development stage
- Preclinical
- Lead developer
- Homestead High School
- Modality
- Peptides
01
Overview
Peptide Nano-Enzymes (PepNzymes) are engineered peptide-based molecular mimics designed for the treatment of anti-N-methyl-D-aspartate (NMDA) receptor autoimmune encephalitis. Developed by researchers at Homestead High School and Moxie Scientist, these PepNzymes are constructed from the NR1 subunit of the NMDA receptor using protein linker design to connect smaller peptides. They are designed to act as stable molecular mimics that specifically bind to and saturate anti-NMDA receptor autoantibodies, thereby preventing them from targeting endogenous NMDA receptors in the brain and mitigating severe neurologic symptoms.
- Other names
- PepNzymes
02
Targets
Anti-NMDA receptor autoantibodies
Beyond the preview
Go deeper on Peptide Nano-Enzymes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Peptide Nano-Enzymes.